We first verified ST6GAL1 overexpression in PDAC patient tissues, then established a tumor driver function for ST6GAL1 using tumor xenograft models and GEM models with dual expression of ST6GAL1 and oncogenic KRAS (KRASG12D). Here, KRAS is linked to neoplasm.